The C9orf72 gene has long been under scrutiny for its involvement in familial ALS, with pathological expansions of a hexanucleotide repeat in this gene serving as a prominent genetic cause. Intriguingly, the recent research delves into the autoimmune responsiveness against the C9orf72 protein itself, rather than just its genetic aberrations, suggesting a broader role of adaptive immunity in neurodegeneration. This study breaks new ground by analyzing whether T cell immune responses, specifically directed against C9orf72 peptides, are exclusive to ALS or characteristic of neurodegeneration in a wider sense.

By comparing immune responses in individuals diagnosed with Parkinson’s disease or Alzheimer’s disease to those in ALS patients and healthy controls, the research team identified that both PD and AD patients exhibited significantly elevated T cell reactivity towards C9orf72 peptides. This unexpected finding challenges the previously held notion that autoimmune responses against C9orf72 are limited to ALS and hints at a ubiquitous immune component traversing multiple neurodegenerative phenotypes.

The T cell response measured predominantly involved the secretion of interferon-gamma (IFNγ), a cytokine closely associated with proinflammatory immune activity. Remarkably, this IFNγ-driven response pattern was similar between PD and AD patients and healthy controls, suggesting a conserved mechanism of immune activation in these groups. Contrarily, the ALS patients displayed a differing cytokine profile, with variations in IL-5 — a cytokine linked to allergic and regulatory immune processes — highlighting a qualitative difference in the autoimmune response.

These nuanced immunological disparities underscore the complexity of neurodegenerative diseases’ pathogenesis, intertwining genetic predispositions, protein misfolding, and immune-mediated inflammation. The dichotomy in cytokine patterns between ALS and other neurodegenerative disorders may reflect unique disease mechanisms or suggest divergent stages or severities of immune involvement.

Crucially, this study utilized robust immunological assays to stimulate patient-derived T cells with synthetic peptides corresponding to the C9orf72 protein, allowing precise quantification of antigen-specific immune responses. This methodological approach provides concrete evidence that the immune system in neurodegenerative patients not only recognizes C9orf72 but mounts functional responses that could potentially exacerbate neuronal damage.

Another significant revelation is the potential for immune cross-reactivity or epitope spreading in patients suffering from different neurodegenerative diseases. If common self-antigens, like C9orf72, serve as targets for pathogenic T cells across these disorders, it raises the possibility of shared therapeutic avenues targeting immune modulation, perhaps slowing disease progression or alleviating symptoms.

The implications of these findings extend into the realm of biomarker development. The distinct patterns of IFNγ and IL-5 secretion in ALS versus PD or AD patients might serve as immune signatures, facilitating diagnosis or prognostication. Monitoring T cell responses against C9orf72 peptides could thus emerge as a novel immunodiagnostic tool specific to neurodegenerative disease subtypes.

Moreover, this research highlights the indispensable role of adaptive immunity in diseases traditionally categorized as neurodegenerative and neuroinflammatory comorbidities. Previously, T cells were not heavily implicated as central players in the pathology of Alzheimer’s or Parkinson’s diseases. This study contradicts that assumption, proposing that immune dysregulation may be more pervasive and perhaps a contributor rather than just a bystander.

Therapeutically, targeting these autoimmune responses offers a tantalizing prospect. For ALS patients, strategies aimed at modulating IFNγ pathways or balancing the IL-5-mediated responses might yield clinical benefits. In PD and AD, understanding the mechanisms driving elevated C9orf72-directed T cell activity could enable interventions that curb neuroinflammation without compromising overall immune competence.

It also invites questions regarding the triggers for such autoimmune phenomena. Does neuronal death unmask antigenic epitopes, initiating a misguided immune attack? Or do systemic immune alterations provoke these reactions, thereby exacerbating neurodegeneration? Future research must endeavor to unravel this chicken-and-egg scenario, determining causality and sequence in autoimmune involvement.

Furthermore, these insights stress the importance of comprehensive patient profiling, integrating genetic, neuropathological, and immunological data to form a holistic picture of neurodegenerative disease mechanisms. Precision medicine approaches tailored to immune profiles might enhance therapeutic responses and outcomes.

This landmark study by Michaelis, Lindestam Arlehamn, Johansson, and colleagues thus paves the way for a deeper understanding of how autoimmune responses to C9orf72 proteins intersect with neurodegenerative disorders beyond ALS. It challenges the scientific community to reconsider fundamental paradigms and to leverage immunology in the quest for more effective treatments for these debilitating conditions.

As research continues to elucidate the interplay between genetics, protein pathology, and immunity, the promise of novel diagnostic biomarkers and immune-targeted therapies brings renewed hope to millions affected worldwide by ALS, Parkinson’s, and Alzheimer’s diseases. The expanding role of T cells in neurodegeneration may ultimately redefine therapeutic strategies and transform patient care.

Subject of Research: Immune system responses to C9orf72 protein in neurodegenerative diseases

Article Title: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis

Article References:
Michaelis, T., Lindestam Arlehamn, C.S., Johansson, E. et al. Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis. Nature (2025). https://doi.org/10.1038/s41586-025-09588-6

Image Credits: AI Generated

The collaborative investigation centered on the role of CD4+ T cells—critical players in the immune system’s adaptive response—in patients afflicted with ALS. These immune cells were found to aberrantly target C9orf72, a protein highly expressed in neurons, effectively marking the nervous system as a target for immune-mediated attack. This self-reactivity underscores a fundamental characteristic of autoimmune diseases, where the body’s defense system erroneously recognizes its own proteins as foreign invaders.

Alessandro Sette, Ph.D., a co-lead on the study from the LJI, emphasized the novelty of these findings: “For the first time, we have unequivocal evidence demonstrating that ALS involves an autoimmune response targeting specific neuronal proteins.” Partnering with Columbia’s David Sulzer, Ph.D., the team used advanced immunological assays to detect heightened levels of inflammation-promoting CD4+ T cells in ALS patients, specifically those reactive against the C9orf72 protein. This discovery shifts the paradigm of ALS research by implicating immune dysregulation as a central contributor to disease pathology.

Surprisingly, the research delineated two distinct subpopulations among ALS patients based on their immune profiles. One subset exhibited highly inflammatory CD4+ T cell responses to C9orf72, correlating with shorter predicted survival times. Conversely, a second group demonstrated a more balanced immune signature, characterized by both inflammatory and regulatory, or anti-inflammatory, CD4+ T cells. These regulatory cells are paramount in mitigating excessive immune activation, thereby potentially slowing neuronal degradation and extending patient longevity.

This immunological dichotomy offers a plausible explanation for the perplexing heterogeneity in ALS progression. Notably, public figures such as Lou Gehrig succumbed rapidly to the disease, while others like Stephen Hawking defied odds by surviving for decades post-diagnosis. The newly identified protective role of regulatory CD4+ T cells suggests that modulating these immune components could become a strategic therapeutic avenue to prolong survival and enhance quality of life for ALS patients.

Further mechanistic insights reveal that under normal circumstances, the immune system balances aggressive responses to eliminate pathogens with counteracting signals that restrain immune activity, thus preserving healthy tissue integrity. ALS patients with longer survival times appear to maintain this delicate immunological equilibrium, where anti-inflammatory T cells temper the destructive potential of their inflammatory counterparts.

Looking forward, the research community anticipates harnessing these insights to develop targeted immunotherapies aimed at augmenting regulatory CD4+ T cell responses while damping harmful inflammation in ALS. Tanner Michaelis, the study’s first author and LJI research technician, highlighted the potential impact of these findings: “Identifying C9orf72 as a specific immune target opens new horizons for treatment strategies that are far more precise than current approaches.”

Moreover, the implications of this research transcend ALS, with co-leader Alessandro Sette proposing that similar autoimmune phenomena may underpin other neurodegenerative disorders, including Parkinson’s, Huntington’s, and Alzheimer’s diseases. This aligns with the emergent field of neuroimmunology, where accumulating evidence implicates immune components in the pathogenesis of multiple neurologic conditions previously thought to be purely degenerative.

The study builds on prior discoveries from the Sette Laboratory that connected autoimmunity and Parkinson’s disease, reinforcing the concept that immune dysregulation is a common denominator in neurodegeneration. Sette stated, “The involvement of immune cells in neurodegenerative diseases is becoming more of a rule than an exception, fundamentally altering our understanding of these pathologies and opening avenues for immune-based interventions.”

This landmark work was recently published in the prestigious journal Nature, signifying a major milestone in neuroimmune research. It was supported by multiple funding sources, including LJI & Kyowa Kirin, the Swedish Research Council, the Freedom Together Foundation, and the National Institute of Neurological Disorders and Stroke, underscoring the broad scientific interest and significance of these findings.

As the field advances, researchers remain cautious yet optimistic, recognizing that translating these discoveries into clinical therapies will necessitate rigorous testing and validation. Nonetheless, the identification of a direct autoimmune response against a neuronal protein in ALS patients marks a paradigm shift that promises to transform diagnostic and therapeutic approaches, offering renewed hope for patients facing this relentless disease.

Subject of Research: Cells
Article Title: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis
News Publication Date: October 1, 2025
Web References: http://dx.doi.org/10.1038/s41586-025-09588-6
References: Alessandro Sette, David Sulzer et al., Nature, 2025
Image Credits: La Jolla Institute for Immunology
Keywords: Neuroscience; Immunogenetics; Immunology; Immune cells; Effector cells; Effector T cells; Immune disorders; Autoimmune disorders; Antigens; Neoantigens; Immune response; Adaptive immune response; T cell activation; Immunoreactivity; Neurons; Amyotrophic lateral sclerosis; Neurological disorders; Neurodegenerative diseases; Neuropathology; Diseases and disorders; Human health; Human biology